Nacho Fries Are Home for Good at Taco Bell Canada
Boldly seasoned, golden fries are now a permanent menu item. No ketchup required
VAUGHAN, ON, May 20, 2025 /CNW/ - It's official: Fans asked, and Taco Bell Canada delivered. Canadians can now get their hands on one of Taco Bell's most iconic global menu items, Nacho Fries, now permanently available at locations nationwide. No limited-time drops or settling for ketchup, just crispy, golden fries, dusted with bold Mexican-inspired spices, dunked in warm nacho cheese sauce, available year-round.
"This is more than just a menu update," said Meera Patel, Marketing Director, Taco Bell Canada. "Canadians have not been shy in professing their love for the elevated taste and flavour profile of Nacho Fries. We heard their cries and are delivering on that, by giving fries the glow up they truly deserve."
Nacho Fries first launched in the U.S. in 2018 and quickly became Taco Bell's most successful product launch of all time, surpassing the iconic Doritos Locos Tacos. The fan passion has been monumental ever since, and the same passion can be found in Canada. They have continued to be the perfect addition to satisfying fans' Taco Bell cravings. Now, Taco Bell Canada is making Nacho Fries a permanent fixture, giving Canadians exclusive, year-round access to the beloved menu item.
This move comes at a time when traditional fries and their classic ketchup sidekick just aren't cutting it for younger Canadians. "We're seeing a shift in taste profiles among Gen Z and Millennials," said Patel. "Ketchup isn't enough anymore. They're looking for bolder flavours and more globally inspired snacks. Nacho Fries answers that call, crisped to perfection, built for dipping, and packed with Mexican-inspired seasoning."
Nacho Fries can be enjoyed on their own, or as part of the crave-worthy Deluxe Box, which includes Nacho Fries with a cheesy dipping sauce, a Cantina Chicken Soft Taco, Chalupa Supreme Beef, Beefy 5-Layer Burrito, and a drink.
Nacho Fries are now available for $3.49 CAD at Taco Bell locations nationwide, in-store, drive-thru, and on the Taco Bell app and website. $3.49 prices do not apply to delivery partner platforms.
For more information, visit tacobell.ca
About Taco Bell CanadaTaco Bell Corp. ("Taco Bell") is a subsidiary of Yum! Brands, Inc. and is the nation's leading Mexican-style quick service restaurant chain. Taco Bell serves tacos, burritos, signature quesadillas, nachos, salads and much more. For locations, information on Taco Bell and to chat with Taco Bell fans, visit us online at our website www.tacobell.ca or any of our other social channels, including on Facebook at www.facebook.com/tacobellcanada, Twitter @TacoBellCanada, Snapchat TACOBELLCANADA, or on Instagram @tacobellcanada.
SOURCE Taco Bell Canada
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2025/20/c9573.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
31 minutes ago
- Business Wire
Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025
SEATTLE--(BUSINESS WIRE)--Bonum Therapeutics, a biotechnology company that is using innovative technology for conditional regulation to create highly active and less toxic medicines, today announced Chief Business Officer Neela Patel, Ph.D., will speak at BIO 2025 on a panel on ' Beyond Bispecifics and ADCs: Conditionally Active Biologics.' Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs. The panel will be held on Wednesday, June 18, 2025, in Room 206AB from 10:15 to 11:15 a.m. ET during the BIO International Convention, which takes place June 16-19, at the Boston International Convention and Exhibition Center. It is open to all registered attendees. Conditionally active biologics (CABs) are an emerging class of drugs that are safer and more efficacious than existing treatments with the potential to overcome the challenges of current state-of-the-art therapies, including ADCs and bispecifics. While companies working in this field are currently focused on oncology and immunology, many of their technologies can be applied to any protein therapeutic where regulation is required to harness a biology for patient benefit. The moderator-led discussion will explore the scientific and commercial landscape for CABs, including types of conditionally active therapeutic modalities currently in research and development, the status of clinical data for these molecules, recent technological advances, and the current and future environment for financings and deals. Patel is a scientist and business development executive with more than 25 years of leadership in drug discovery and development, project and portfolio management, and pipeline development through external innovation. Prior to joining Bonum in 2022, she was part of the executive team at Good Therapeutics, where, as Chief Business Development Officer she co-led the company's acquisition by Roche and the subsequent spinout of Bonum. She will be joined by four panelists representing different perspectives on the technology's potential and challenges, including an investor, an expert in drug development from pharma and scientist executives from biotechnology companies with technologies for regulating biologic therapeutics. Alexandra Cantley, Ph.D., Partner, Polaris Partners Stephen Demerast, Ph.D., Chief Scientific Officer, Tentarix Biotherapeutics Randi Isaacs, MD, Chief Medical Officer, Werewolf Therapeutics John C. Lin, MD, Ph.D., SVP, Immuno-Oncology, Head of Bispecifics R&D, Regeneron Pharmaceuticals Moderator: Michael C. Rice, MS, MBA, SVP, Advanced Therapeutics, Lumanity About Bonum Therapeutics Bonum Therapeutics is a privately held biotechnology company that uses a novel antibody-based mechanism to create regulated and targeted, highly active, and less toxic medicines. Bonum's most advanced program is in preclinical development. The company was founded in 2022 as a spinout of Good Therapeutics, following the sale of Good to Roche in September 2022 for $250 million, plus milestones. Bonum's unique approach takes advantage of the ability of an antibody to bind specifically and competitively to two distinct antigens – a dual-binding antibody (DBA). The technology brings the power and specificity of an antibody to therapeutic control and is applicable to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company is backed by a group of leading venture investors including Rivervest Venture Partners, Roche Venture Fund, Digitalis Ventures, American Century Investments, Codon Capital, and Vivo Capital. For more information, please visit our website at and connect with us on LinkedIn and Bluesky.
Yahoo
31 minutes ago
- Yahoo
Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025
Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics SEATTLE, June 10, 2025--(BUSINESS WIRE)--Bonum Therapeutics, a biotechnology company that is using innovative technology for conditional regulation to create highly active and less toxic medicines, today announced Chief Business Officer Neela Patel, Ph.D., will speak at BIO 2025 on a panel on "Beyond Bispecifics and ADCs: Conditionally Active Biologics." The panel will be held on Wednesday, June 18, 2025, in Room 206AB from 10:15 to 11:15 a.m. ET during the BIO International Convention, which takes place June 16-19, at the Boston International Convention and Exhibition Center. It is open to all registered attendees. Conditionally active biologics (CABs) are an emerging class of drugs that are safer and more efficacious than existing treatments with the potential to overcome the challenges of current state-of-the-art therapies, including ADCs and bispecifics. While companies working in this field are currently focused on oncology and immunology, many of their technologies can be applied to any protein therapeutic where regulation is required to harness a biology for patient benefit. The moderator-led discussion will explore the scientific and commercial landscape for CABs, including types of conditionally active therapeutic modalities currently in research and development, the status of clinical data for these molecules, recent technological advances, and the current and future environment for financings and deals. Patel is a scientist and business development executive with more than 25 years of leadership in drug discovery and development, project and portfolio management, and pipeline development through external innovation. Prior to joining Bonum in 2022, she was part of the executive team at Good Therapeutics, where, as Chief Business Development Officer she co-led the company's acquisition by Roche and the subsequent spinout of Bonum. She will be joined by four panelists representing different perspectives on the technology's potential and challenges, including an investor, an expert in drug development from pharma and scientist executives from biotechnology companies with technologies for regulating biologic therapeutics. Alexandra Cantley, Ph.D., Partner, Polaris Partners Stephen Demerast, Ph.D., Chief Scientific Officer, Tentarix Biotherapeutics Randi Isaacs, MD, Chief Medical Officer, Werewolf Therapeutics John C. Lin, MD, Ph.D., SVP, Immuno-Oncology, Head of Bispecifics R&D, Regeneron Pharmaceuticals Moderator: Michael C. Rice, MS, MBA, SVP, Advanced Therapeutics, Lumanity About Bonum Therapeutics Bonum Therapeutics is a privately held biotechnology company that uses a novel antibody-based mechanism to create regulated and targeted, highly active, and less toxic medicines. Bonum's most advanced program is in preclinical development. The company was founded in 2022 as a spinout of Good Therapeutics, following the sale of Good to Roche in September 2022 for $250 million, plus milestones. Bonum's unique approach takes advantage of the ability of an antibody to bind specifically and competitively to two distinct antigens – a dual-binding antibody (DBA). The technology brings the power and specificity of an antibody to therapeutic control and is applicable to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company is backed by a group of leading venture investors including Rivervest Venture Partners, Roche Venture Fund, Digitalis Ventures, American Century Investments, Codon Capital, and Vivo Capital. For more information, please visit our website at and connect with us on LinkedIn and Bluesky. View source version on Contacts Bonum Contact: Neela Patel, Therapeutics(425) 375-5369patel@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
It's a three-peat! Questrade leads annual ranking as MoneySense's Best Online Broker in Canada again for 2025
Online brokerage applauded for its surprise move to offer $0 commission trading, as well as its stellar investing platforms, customer service, and financial education offerings MoneySense Seal TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Questrade ( -- Canada's #1 rated* online brokerage -- is honoured to share that it has retained the title of MoneySense's Best Online Broker in Canada for 2025, landing atop the ranking for a third consecutive year. The annual MoneySense review, conducted in partnership with research firm Surviscor, assesses and compares Canadian online brokerages across four pillars of investor experience including desktop and mobile platforms, service efficacy, and commissions and fees. 'Reclaiming the title of Best Online Broker in Canada adds to an already eventful year for Questrade with our move to offer $0 commission trading alongside our introduction of real-time fractional trading and Questrade Plus,' said Rob Galaski, Chief Journey Officer, Questrade. 'This recognition stands as another powerful acknowledgement of our team's work to deliver Canada's most complete and compelling investment offering, furthering our mission to help all Canadians become much more financially successful and secure.' In another standout year where Questrade outperformed its peers across many of the investor experience categories, it was applauded for its surprise move to introduce $0 commission trading, as well as its reliable customer service experience, industry-leading digital investment platforms, and ongoing commitment to investor education. 'We're proud to once again name Questrade as MoneySense's Best Online Broker in Canada for 2025,' said Natasha Macmillan, Senior Business Director, MoneySense. 'Questrade leads the way with a robust, user-focused platform that prioritizes accessibility, innovation, and exceptional service, delivering genuine value to investors at every experience level. Its unwavering commitment to enhancing the investor experience, education, and ongoing support truly sets Questrade apart from the competition.'Adding to the repeat recognition, MoneySense's 2025 review also named Questrade as best broker for new and seasoned investors, $0 commission trading, user experience, and account experience, highlighting the online brokerage's attention to the evolving needs and preferences of active and passive investors alike. For a full breakdown of the rankings and explanation of all the criteria used, please visit the following link: Questrade Questrade, Inc. ('Questrade') is changing the Canadian financial services industry by leveraging technology to lower fees while providing a viable alternative to traditional financial investment options, thereby allowing Canadians to Keep More of their Money. As a leader and innovator in financial services, Questrade is a trusted ally that advocates for consumers, focused on improving value. With 25 years of challenging the status quo as one of Canada's leading, non-bank online brokerages and over $50 billion in assets under administration, Questrade and its affiliates provide financial products and services, including securities and foreign currency investments. For more information, visit or on Facebook and X (formerly Twitter) @Questrade. Questrade, Inc. is a registered investment dealer, a member of the Canadian Investment Regulatory Organization (CIRO), and a member of the Canadian Investor Protection Fund (CIPF). Questrade is a wholly owned subsidiary of Questrade Financial Group Inc. *MoneySense 2025 Media Contact For more information, please contact J.R Gabriel, Questrade Financial Group at: jgabriel@ A photo accompanying this announcement is available at while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
